Abstract:In a pancreatic tumor microenvironment, activated pancreatic stellate cells (PSCs) produce extracellular matrix (ECM) to form a barrier to drug penetration. Moreover, the interaction between cancer cells and activated PSCs promotes the tumor growth. Vitamin D receptor (VDR), as a key regulator to promote the recovery of PSCs to the resting state, is an attractive therapeutic target for pancreatic cancer. Herein, we reported the design and synthesis of 57 nonsecosteroidal VDR modulators based on the skeleton of phenyl-pyrrolyl pentane. Among them, compounds C4, I5, and I8 exhibited excellent VDR affinity and effective inhibition of the activation of PSCs, as well as potent suppression of the interaction between cancer cells and PSCs in vitro. In vivo, compound I5 combined with gemcitabine achieved efficacious antitumor activity without causing hypercalcemia. In conclusion, the compounds designed in our study can remodel the tumor microenvironment and are expected to be candidates for the treatment of pancreatic cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01197?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01197</a>.(Table S1) Cell toxicity of all target compounds against LTC-14; (Figure S1) cell toxicity of representative compounds against DSL-6A/C1 cells; (Figure S2) relative BLI intensities of mice that received different treatments; (Figure S3) inhibition rate of tumor growth after tumor-bearing mice received different treatments; (Figure S4) relative fluorescence intensities of α-SMA after mice received different treatments; (Figure S5) survival percentages of mice that received different treatments; (Figure S6) in vivo hypercalcemic effects in the orthotopic transplantation pancreatic cancer model; NMR spectra information; HPLC traces; and 1H NMR and 13C NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_001.pdf">PDF</a>)Molecular Formula Strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01197/suppl_file/jm0c01197_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis

Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer

Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Inhibitory Effect of Metformin Combined with Gemcitabine on Pancreatic Cancer Cells in Vitro and in Vivo.

Transcytosis Mediated Deep Tumor Penetration for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer

Sequential Delivery of Nanoformulated Α-Mangostin and Triptolide Overcomes Permeation Obstacles and Improves Therapeutic Effects in Pancreatic Cancer.

Sequential Therapy for Pancreatic Cancer by Losartan- and Gemcitabine-Loaded Magnetic Mesoporous Spheres

Nitric Oxide-Induced Stromal Depletion for Improved Nanoparticle Penetration in Pancreatic Cancer Treatment.

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.

Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma

Metformin‐Mediated Immunosuppressive Microenvironment Remodeling in Combination with Chemotherapy Via a Spatial‐Specific Multi‐Responsive Carrier‐Free Self‐Assembled Nanoparticle

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib

Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment

Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy

Theranostic Nanoparticles With Controlled Release Of Gemcitabine For Targeted Therapy And Mri Of Pancreatic Cancer

Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer

Temperature‐Sensitive Magnetic Drug Carriers for Concurrent Gemcitabine Chemohyperthermia

Co-delivery of Autophagy Inhibitor and Gemcitabine Using a Ph-Activatable Core-Shell Nanobomb Inhibits Pancreatic Cancer Progression and Metastasis.